HELEN KIM: Open Payments
NPI 1497380356 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,129 in 90 payments from 19 companies in 2025. Trend: 2023 $1,068 · 2024 $1,473 · 2025 $2,129
Food & beverage: $2,129
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $471 |
| Vanda Pharmaceuticals Inc. | 10 | $288 |
| ABBVIE INC. | 16 | $272 |
| Otsuka America Pharmaceutical, Inc. | 10 | $246 |
| E.R. Squibb & Sons, L.L.C. | 5 | $199 |
| Teva Pharmaceuticals USA, Inc. | 8 | $140 |
| Alkermes, Inc. | 5 | $103 |
| Indivior Inc. | 3 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
| Braeburn Inc. | 2 | $43 |
Products named: INGREZZA, VRAYLAR, HETLIOZ, COBENFY, ABILIFY ASIMTUFII, REXULTI, ARISTADA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
